Antioxidant capacity and structural changes of human serum albumin from patients in advanced stages of diabetic nephropathy and the effect of the dialysis

Molecular and Cellular Biochemistry

Volumn 404, Issue 1-2, 2015, Pages 193-201

  Rosas Díaz, Marisol ^a   Camarillo Cadena, Menandro ^b   Hernández Arana, Andrés ^b   Ramón Gallegos, Eva ^c   Medina Navarro, Rafael ^a  

^a Center for Biomedical Research of Michoacán CIBIMI IMSS   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Albumin conformational changes; Diabetes; Diabetic nephropathy; Hemodialysis; Human serum albumin; Oxidative stress

Indexed keywords

HUMAN SERUM ALBUMIN; THIOL GROUP; TRYPTOPHAN; SERUM ALBUMIN;

ADULT; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CIRCULAR DICHROISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE CLASSIFICATION; FEMALE; FLUORESCENCE SPECTROSCOPY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; ADVERSE EFFECTS; BLOOD; CHEMISTRY; DIABETIC NEPHROPATHIES; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; RENAL REPLACEMENT THERAPY;

CIRCULAR DICHROISM; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84941741965     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2378-2     Document Type: Article

References (42)

1. Zelmanovitz T, Gerchman F, Balthazar AS, Thomazelli FCS, Jorge D, Matos JD, Canani LH (2009) Diabetic nephropathy. Diabetol Metab Syndr 1:1–17
2. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius C, Finocchiaro M, Mangiameli A, Di Mauro M, Stella AMG, Castellino P (2007) Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 12:299–306
3. Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean. Brit J Pharmacol 142:231–255
4. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582:1783–1787
5. Otagiri M, Chuang VT (2009) Pharmaceutically important pre- and posttranslational modifications on human serum albumin. Biol Pharm Bull 32:527–534
6. Christodoulou J, Sadler PJ, Tucker A (1994) A new structural transition of serum albumin dependent on the state of Cys34. Eur J Biochem 225:363–368
7. Varshney A, Rehan M, Subbarao N, Rabbani G, Khan RH (2011) Elimination of endogenous toxin, creatinine from blood plasma depends on albumin conformation: site specific uremic toxicity and impaired drug binding. PLoS ONE 6:1–15
8. Oettl K, Stauber RE (2007) Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 151:580–590
9. Turell L, Carballal S, Botti H, Radi R, Alvarez B (2009) Oxidation of the albumin thiol to sulfenic acid and its implications in the intravascular compartment. Braz J Med Biol Res 42:305–311
10. Himmelfarb J, McMonagle E (2001) Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358–363
11. Faure P, Tamisier R, Baguet JP, Favier A, Halimi S, Levy PE, Pepin J (2008) Impairment of serum albumin antioxidant properties in obstructive sleep apnoea syndrome. Eur Respir J 31:1046–1053
12. Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S (2004) Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 20:351–357
13. Faure P, Troncy L, Lecomte Wiernsperger MN, Lagarde M, Ruggiero D, Halimi S (2005) Albumin antioxidant capacity is modified by methylglyoxal. Diabetes Metab 31:169–177
14. Terawaki H, Era S, Nakayama M, Hosoya T (2011) Decrease in reduced-form albumin among chronic kidney disease patients: new insights in cardiovascular complications. Ther Apher Dial 15:156–160
15. Matsuyama Y, Terawaki H, Terada T, Era S (2009) Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 13:308–315
16. Taverna M, Marie AL, Mira JP, Guidet B (2013) Specific antioxidant properties of human serum albumin. Ann Intensive Care 3:4
17. Cohen MP (2003) Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys 419:25–30
18. Rondeau P, Armenta S, Caillens H, Chesne S, Bourdon E (2007) Assessment of temperature effects on beta-aggregation of native and glycated albumin by FTIR spectroscopy and PAGE: relations between structural changes and antioxidant properties. Arch Biochem Biophys 460:141–150
19. Wratten ML, Sereni L, Tetta C (2001) Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 23:563–571
20. Soejima A, Kaneda F, Manno S, Matsuzawa N, Kouji H, Nagasawa T, Era S, Takakuwa Y (2002) Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kidney Dis 39:1040–1046
21. American Diabetes Association (2013) Standards of medical care in diabetes–2013. Diabetes Care 36:S11–S66
22. Riener CK, Kada G, Gruber HJ (2002) Quick measurement of protein sulfhydryls with Ellman’s reagent and with 4, 4′-dithiodipyridine. Anal Bioanal Chem 373:266–276
23. Medina-Navarro R, Durán-Reyes G, Díaz-Flores M, Vilar-Rojas C (2010) Protein antioxidant response to the stress and relationship between molecular structure and antioxidant function. PLoS ONE 5:1–10
24. Moreno SN, Stolze K, Janzen EG, Mason RP (1998) Oxidation of cyanide to the cyanyl radical by peroxidase/H2O2 systems as determined by spin trapping. Arch Biochem Biophys 265:267–271
25. Halliwell B, Gutteridge JM (1999) Antioxidant defenses. Free radicals in biology and medicine, 3rd edn. Oxford University Press, New York, pp 105–245
26. Kalyanaraman B, Janzen EG, Mason RP (1985) Spin trapping of the azidyl radical in azide/catalase/H2O2 and various azide/peroxidase/H2O2 peroxidizing systems. J Biol Chem 260:4003–4006
27. Chapple I, Mason GI, Garner I, Matthews JB, Thorpe GH, Maxwell SR, Whitehead TP (1997) Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid. Ann Clin Biochem 34:412–421
28. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
29. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4:2411–2423
30. Peterman BF, Laidler KJ (1980) Study of reactivity of tryptophan residues in serum albumins and lysozyme by N-bromosuccinamide fluorescence quenching. Arch Biochem Biophys 199:158–164
31. Medina-Navarro R, Corona-Candelas I, Barajas-González S, Díaz-Flores M, Durán-Reyes G (2014) Albumin antioxidant response to stress in diabetic nephropathy progression. PLoS ONE 9:1–13
32. Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I, Suzuki E, Hirayama K (2006) Identification and characterization of oxidized human serum albumin. FEBS J 273:3346–3357
33. Dockal M, Carter DC, Ruker F (1999) The three recombinant domains of human serum albumin. J Biol Chem 274:29303–29310
34. Curry S (2009) Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharm 24:342–357
35. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K (1999) Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng 12:439–446
36. Greenfield NJ (2006) Analysis of the kinetics of folding of proteins and peptides using circular dichroism. Nat Protoc 1:2891–2899
37. Sattarahmady N, Moosavi-Movahedi AA, Habibi-Rezaei M, Ahmadian S, Saboury AA, Heli H, Sheibani N (2008) Detergency effect of nanofibrillar amyloid formation on glycation of human serum albumin. Carbohydr Res 343:2229–2234
38. Kisugi RT, Kouzuma T, Yamamoto S, Akizuki H, Miyamoto Y, Someya J, Yokoyama I, Abe N, Hirai A, Ohnishi A (2007) Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 382:59–64
39. Nagaoka S, Cowger ML (1978) Interaction of bilirubin with lipids studied by fluorescence quenching method. J Biol Chem 253:2005–2011
40. Guerin-Dubourg A, Catan AA, Bourdon E, Rondeau P (2012) Structural modifications of human albumin in diabetes. Diabetes Metab 38:171–178
41. Zoellner H, Hou JY, Hochgrebe T, Poljak A, Duncan MW, Golding J, Henderson T, Lynch G (2001) Fluorometric and mass spectrometric analysis of nonenzymatic glycosylated albumin. Biochem Biophys Res Commun 248:83–89
42. Zoellner H, Siddiqui S, Kelly E, Medbury H (2009) The anti-apoptotic activity of albumin for endothelium is inhibited by advanced glycation end products restricting intramolecular movement. Cell Mol Biol Lett 14:575–586